It covers why semaglutide and tirzepatide work on different timelines, why appetite suppression arrives before weight loss does, why your neighbor lost ten pounds in month one while you lost three, and what the clinical trial data actually says about realistic expectations
These data are consistent with one of two scenarios, either (1) direct peptide-stimulated inhibition of GLP-1R and Y1-R on -cells, or (2) indirect peptide-mediated insulin release leading to inhibition of glucagon release, as observed in previous studies 50,51
[3] [5] Animal studies have shown effects on thyroid C-cells, so patients should report any neck mass, hoarseness, or difficulty swallowing
There are many people who are against these drugs because of how they contribute to the idea that we can and should all be thin, she says theres a fear that this will contribute to more eating disorders, and that people will never be able to accept their bodies, theyll always be told: Well, you could be thinner, just use this medicine. For now, what clinicians can do is what most of them are already doing: screening patients for a history of eating disorders before prescribing GLP-1s
Tirzepatide should not be used in patients with type 1 diabetes mellitus
Think of it as the comfortable middle ground